Article Sidebar
Views pdf: 35
LONG-TERM OUTCOMES OF PATIENTS WITH GRAVES’ OPHTHALMOPATHY
Main Article Content
Abstract
The natural course of Graves' ophthalmopathy (GO) is described by Rundle curve with two phases active phase about 6-24 months and static phase or inactive phase. Glucocorticoids are currently the first-line immunosuppressant drugs for the treatment of active Graves' ophthalmopathy, but the effectiveness is inactive. In the inactive group, its course is still a question for many clinical practitioners. This prospective, non-controlled clinical intervention study aimed to evaluate the progression of eye lesions in 40 patients with GO who developed GO within 6 months from December 2020 to December 2021 at the Central Eye Hospital and were continuously monitored for 24 months. The study results showed that after 24 months, 67.5% improved, 32.5% were stable, and no patients worsened. After 24 months, the convexity of the study group decreased by -1.79 ± 0.85 mm, MRD1 decreased by -1.99 ± 0.67 mm, the total diameter of the 4 rectus muscles decreased by -1.33 ± 0.46 mm. The reduction of proptosis, upper eyelid retraction, and the total diameter of the 4 rectus muscles between the 2 groups active and inactive did not differ (p<0.001). The diplopia and quality of life of the active group improved better than the inactive group.
Article Details
Keywords
Graves’ eye disease, proptosis, upper eyelid retraction, diplopia, extraocular muscle enlargement
References
2. Bartalena, L., et al., The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J, 2016. 5(1): p. 9-26.
3. Rundle, F.F., Management of exophthalmos and related ocular changes in Graves' disease. Metabolism, 1957. 6(1): p. 36-48.
4. Tang, C., et al., Glucocorticoid therapy reduces ocular hypertension in active moderate-severe thyroid-associated orbitopathy. BMC Endocr Disord, 2022. 22(1): p. 235.
5. Lee, D.C., et al., Course of upper eyelid retraction in thyroid eye disease. Br J Ophthalmol, 2020. 104(2): p. 254-259.
6. Zloto, O., et al., Quality of life of patients with thyroid eye disease: 3-year follow-up in a multidisciplinary clinic in Israel. Graefes Arch Clin Exp Ophthalmol, 2021. 259(7): p. 2009-2015.
7. Son, B.J., S.Y. Lee, and J.S. Yoon, Evaluation of thyroid eye disease: quality-of-life questionnaire (TED-QOL) in Korean patients. Can J Ophthalmol, 2014. 49(2): p. 167-73.
8. Lee, H.B., I.R. Rodgers, and J.J. Woog, Evaluation and management of Graves' orbitopathy. Otolaryngol Clin North Am, 2006. 39(5): p. 923-42.